Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP

Enfortumab vedotin in combination with pembrolizumab is a potential new standard of care for 1L la/mUC

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC

Personalised systemic treatment in advanced prostate cancer

World Bladder Cancer Patient Coalition

DNA methylation profile of prostate cancer aggressiveness in Ghana

ESMO 2023: Highlights and analysis

Adjuvant radiotherapy has no benefit following radical prostatectomy

Where do we stand with mCRPC?

PARPi combinations to treat patients with mCRPC

Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer